Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
35.9 USD | -1.03% | +4.80% | +63.43% |
May. 02 | Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target | MT |
Apr. 19 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.43% | 1.46B | |
-1.63% | 103B | |
+7.04% | 101B | |
+4.40% | 23.07B | |
-12.04% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.60% | 16.94B | |
+6.28% | 14.07B | |
+37.65% | 12.35B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12